Quốc gia: Canada
Ngôn ngữ: Tiếng Anh
Nguồn: Health Canada
TETRAKIS [CU(MIBI)4]BF4
CURIUM CANADA INC
V09GA01
TECHNETIUM (99m Tc) SESTAMIBI
1MG
KIT
TETRAKIS [CU(MIBI)4]BF4 1MG
INTRAVENOUS
15G/50G
Schedule C
ROENTGENOGRAPHY
Active ingredient group (AIG) number: 0152590001; AHFS:
APPROVED
2018-12-07
_ _ _Kit for the preparation of Technetium Tc 99m Sestamibi Injection _ _Page 1 of 28_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION KIT FOR THE PREPARATION OF TECHNETIUM TC 99M SESTAMIBI INJECTION Freeze-dried Powder for Solution, 1 mg/vial and Intravenous Professed Standard Radiodiagnostic Agent (Myocardial Imaging), V09GA0 Curium Canada Inc. 2572 Boul. Daniel-Johnson, Suite 217 & 220 Laval, QC, H7T-2R3 CANADA www.curiumpharma.com Date of Initial Authorization: JAN 21,2016 Date of Revision: NOV 9. 2022 Submission Control Number: 265394 _ _ _ _ _Kit for the preparation of Technetium Tc 99m Sestamibi Injection _ _Page 2 of 28_ RECENT MAJOR LABEL CHANGES Section 4: Dosage and Administration, 4.1: Dosing Considerations 06/2022 Section 9: Drug Interactions, 9.2: Drug Interactions Overview 06/2022 Section 9: Drug Interactions, 9.4: Drug-Drug Interactions 06/2022 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED . RECENT MAJOR LABEL CHANGES............................................................................................ 2 TABLE OF CONTENTS .............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ..................................................................... 5 1 INDICATIONS .............................................................................................................. 5 1.1 Pediatrics .......................................................................................................... 5 1.2 Geriatrics........................................................................................................... 5 2 CONTRAINDICATIONS ................................................................................................. 5 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ............................................................ 5 4 DOSAGE AND ADMINISTRATION................................................................ Đọc toàn bộ tài liệu